Rieken M, et al. - This study sought to describe outcomes of patients with TaT1 urothelial carcinoma of the bladder stratified by the European Association of Urology (EAU) categories and to compare them with European Organization for Research and Treatment of Cancer (EORTC) risk groups to assess the rate and effect of reclassification. The EAU categories reclassifies 37.9% patients into a higher risk group of recurrence and 11.8% into a higher risk of progression compared to EORTC risk stratification. However, the novel risk stratification ascribed most patients to the same treatment as the more complex EORTC tables and could be regarded as an alternative tool for treatment decision-making.